This diagnostic approach enables earlier risk stratification and proactive care, potentially reducing severe complications and hospital burden. Its biomarker-based framework enhances diagnostic accuracy and supports faster clinical decision-making, offering a valuable tool for healthcare systems in dengue-endemic regions seeking improved patient management strategies.

‍

Dengue infections can progress rapidly from mild symptoms to severe, life-threatening complications. Current clinical assessments may not always detect early biological changes that signal worsening disease, making timely intervention challenging. Delayed identification of severe cases can lead to increased morbidity, strain on healthcare resources, and poorer patient outcomes.

‍

The method involves testing blood samples to quantify levels of kynurenine pathway metabolites and cytokines associated with immune response and disease progression. By analysing these biomarker profiles, healthcare providers can stratify patients according to disease severity and identify those at higher risk of complications, enabling closer monitoring and targeted clinical management.

‍

The innovation lies in the use of combined metabolic and immunological biomarkers to provide a more precise and early-stage assessment of dengue severity. By integrating biochemical pathway analysis with clinical classification, the method moves beyond symptom-based evaluation to a more predictive and data-driven diagnostic approach.

‍